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Abstract
Background: More than half of all antibiotic prescriptions in general practice are issued for respiratory
tract infections (RTIs), despite convincing evidence that many of these infections are caused by viruses.
Frequent misuse of antimicrobial agents is of great global health concern, as we face an emerging
worldwide threat of bacterial antibiotic resistance. There is an increasing need to identify determinants
and patterns of antibiotic prescribing, in order to identify where clinical practice can be improved.
Methods/Design: Approximately 80 peer continuing medical education (CME) groups in southern
Norway will be recruited to a cluster randomized trial. Participating groups will be randomized either to
an intervention- or a control group. A multifaceted intervention has been tailored, where key components
are educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer
Academic Detailers (Rx-PADs), who are trained GPs, will conduct the educational outreach visits. During
these visits, evidence-based recommendations of antibiotic prescriptions for RTIs will be presented and
software will be handed out for installation in participants PCs, enabling collection of prescription data.
These data will subsequently be linked to corresponding data from the Norwegian Prescription Database
(NorPD). Individual feedback reports will be sent all participating GPs during and one year after the
intervention. Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and
change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic
intervention.
Discussion: Improvement of prescription patterns in medical practice is a challenging task. A thorough
evaluation of guidelines for antibiotic treatment in RTIs may impose important benefits, whereas
inappropriate prescribing entails substantial costs, as well as undesirable consequences like development
of antibiotic resistance. Our hypothesis is that an educational intervention program will be effective in
improving prescription patterns by reducing the total number of antibiotic prescriptions, as well as
reducing the amount of broad-spectrum antibiotics, with special emphasis on macrolides.
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Acute respiratory tract infections (RTIs) are important tar-
gets for educational strategies aimed at reducing inappro-
priate prescriptions of antibiotics, because such infections
have a high prevalence in general practice [1], and because
antibiotics are commonly prescribed even for those ill-
nesses that have a predominantly viral etiology, such as
common colds and acute bronchitis [2-4].
Inappropriate use of antibiotics is of great public health
concern, both nationally and globally, because of its asso-
ciation with increased antibiotic resistance in the commu-
nity [5,6]. Bacterial strains that are increasingly resistant to
antimicrobial agents pose a severe health threat, and of
particular concern is community-acquired infections
caused by multi-drug-resistant Streptococcus pneumoniae
[7,8], macrolide-resistant Streptococcus pyogenes [9-11],
and methicillin-resistant Staphylococcus aureus [12,13].
Antimicrobial resistance is an increasing problem world-
wide, and several countries have implemented surveil-
lance systems in recent years. The Norwegian surveillance
program for antimicrobial resistance (NORM) was estab-
lished in 1999 and has reported yearly on the epidemiol-
ogy of antimicrobial resistance and the usage of
antimicrobial agents [14]. Antimicrobial susceptibility
data on common pathogens such as Klebsiella species,
Haemophilus influenzae, Staphylococcus aureus, and Strepto-
coccus pyogenes confirm that antimicrobial resistance is
still a limited problem in Norway [15]. This also applies
for the prevalence of macrolide-resistant Streptococcus
pneumoniae (MRSP), which has increased dramatically in
several European countries [16], but is still a relatively
limited problem in Northern Europe [17,18].
Low levels of antimicrobial resistance in Scandinavian
countries is probably due to relatively conservative anti-
microbial prescription patterns, compared to southern
Europe and USA [19]. Nevertheless, an increase in mac-
rolide resistance in Streptococcus pneumoniae blood culture
isolates has also been observed in Norway; from 2.4% in
2000, 4.8% in 2002 and 6.0% in 2003, to 9.7% in 2004
[14]. Macrolides are recommended as second-line alterna-
tives in the treatment of RTIs, because the prevalence of
non-penicillin-susceptible Streptococcus pneumoniae is
below 3% in Norway [20]. They are recommended only
for patients who are allergic to penicillin or are suspected
of having atypical pneumonia or pertussis. Thus, the
increase in MRSP is of clinical concern as well as public
health interest.
In Norway, more than 90% of all antibiotic prescriptions
are issued by general practitioners (GPs) [21], and 60% of
these prescriptions are issued as treatment for common
RTIs, for which the Norwegian national guidelines recom-
mend penicillin V as the drug of choice [22]. Generally,
the number of antibiotic prescriptions has raised with
more than 30% in Norway during the last two decades
[21].
Norwegian GPs' prescription patterns of antibiotics were
studied (1988–89) in the Norwegian county of Møre and
Romsdal [4,23], where more than 95% of the GPs in the
county participated in the survey. Of all RTIs, acute bron-
chitis, otitis, and upper respiratory tract infection were the
most frequently recorded diagnoses that prompted an
antibiotic prescription. Penicillin V was the most com-
monly prescribed antibiotic for patients suffering otitis,
upper respiratory tract infection, tonsillitis, and sinusitis,
whereas erythromycin and tetracyclines were most fre-
quently prescribed for lower RTIs [4]. Seven out of 10 chil-
dren (aged 0–12 years) who were prescribed an antibiotic,
received it as a result of a RTI [23]. More than eight out of
10 children who consulted a GP for sinusitis, tonsillitis,
acute bronchitis, or pneumonia were prescribed an antibi-
otic [23]. For ear infections, an antibiotic prescription was
given in 44% of all consultations, but this proportion
increased to 64% when follow-up contacts for this diag-
nosis were excluded [23]. Penicillin V was the most fre-
quently prescribed antibiotic for children with ear
infection, upper respiratory tract infection, tonsillitis,
sinusitis, and skin infections, whereas erythromycin was
given to a considerable proportion of those with bronchi-
tis or pneumonia [23].
Acute otitis media (AOM) is the most common bacterial
infection in children [24]. In the Western world, most
cases of AOM remit spontaneously and without complica-
tions [25]. The prevalence of antibiotic treatment for
AOM varies in different countries, between 31% in The
Netherlands and 98% in USA, Australia and New Zealand
[26]. In The Netherlands, treatment of symptoms without
antimicrobials has been adopted as the routine initial
treatment for otitis media, and this policy is associated
with decreased emergence of resistance among organisms
commonly found in AOM [27]. In a meta-analysis, Del
Mar et al. [28] concluded that early use of antibiotics pro-
vided only modest benefit for AOM, and that 17 children
with AOM must be treated with antibiotics in order to pre-
vent one child from experiencing pain 2–7 days after pres-
entation of symptoms. It is likely that AOM is the reason
for many unnecessary prescriptions for antibiotics, espe-
cially when broad-spectrum antibiotics are used [26]. In a
study from a Norwegian emergency department setting,
90% of 819 children (aged 1–15 years) with AOM
received treatment with antibiotics, and 18% of these pre-
scriptions where for antibiotics other than penicillin V
[29].Page 2 of 12
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of diseases that is generally classified into the categories of
acute and chronic [30]. The diagnosis of acute sinusitis in
GP settings is a challenging task [31], and although many
instances of acute sinusitis are of bacterial origin, most
cases are thought to be inflammatory rather than infec-
tious [30]. The issues of the pathogenesis and treatment of
sinusitis are ongoing areas of controversy and active inves-
tigation [30,31].
Steinman et al. [32] found that broad-spectrum antibiot-
ics were prescribed in more than half of all cases of RTIs in
adults, and that there was a wide variation in prescribing
of such agents among different groups of patients and
physicians, even after controlling for diagnosis and
comorbidities. In a large, cross-national database study of
antibiotic use and its associations with resistance, Goos-
sens et al. [33] investigated outpatient antibiotic use in 26
countries in Europe that provided internationally compa-
rable distribution or reimbursement data in the period
1997–2002, and found that prescription patterns varied
greatly; the highest rate was in France and the lowest was
in The Netherlands. A shift from the old narrow-spectrum
antibiotics to the new broad-spectrum antibiotics (like the
newer macrolides) were observed, as well as striking sea-
sonal fluctuations with winter peaks in countries with
high yearly use of antibiotics [33].
The use of macrolides for common airways infections
deviate from current Norwegian national guidelines
[34,35], and Brubakk and Bruun [36] underline that indi-
cations for macrolides in airway illnesses are limited to
infections with Bordetella pertussis and Mycoplasma pneu-
monia.
In outpatients, macrolide consumption is closely linked
to the development of streptococcal resistance. In Finland,
there was a steady and statistically significant decline in
erythromycin resistance among group A streptococcal iso-
lates from throat-swab and pus samples after a reduction
in the use of macrolide antibiotics in outpatient therapy
[37]. Evidence from Sweden and New Zealand also dem-
onstrate that a reduction in antibiotic use can be accom-
panied by a reduction in antibiotic resistance [38,39].
In a recent review issued by the Cochrane Collaboration,
Arroll [40] argues that antibiotics have only a limited role
in the treatment of AOM, sore throat, acute maxillary
sinusitis, common cold, and acute purulent rhinitis.
Except for radiologically proven acute maxillary sinusitis,
antibiotics are not recommended as initial treatment for
any of the conditions mentioned above [40].
Questions on validity and relevance of individual studies
that are summarized in systematic reviews may be
assessed differently by various reviewer groups, and may
explain why the guidelines from the Infectious Disease
Society of America (2002) recommend routine treatment
for otitis media [41], whereas the Cochrane review repre-
sent a more cautious line and remain consistent with the
older guidelines in not recommending antibiotics as a
first-line treatment [40].
Over the past decade, general practice prescribing of anti-
biotics to children has halved in England, and this reduc-
tion has not been associated with an increase in
admission to hospital for possible complications, like
peritonsillar abscess or rheumatic fever [42]. The decline
in use is due to a substantial reduction in prescriptions by
GPs [42]. After 1997, the proportion of prescriptions
taken to a pharmacist also declined, possibly indicating
that GPs were adopting the "delayed prescribing" policy
(issuing prescriptions with advice to parents to wait and
see if their child's condition improved spontaneously)
that was introduced after widespread dissemination of
trial results supporting this practice [43].
An important aspect in the strategy of "delayed prescrip-
tions" is the necessary management of patients' requests
for specific treatments. Evidence suggests that a majority
of patients feel that antibiotics are an appropriate treat-
ment for a wide range of respiratory tract symptoms, and
that doctors will prescribe antibiotics for them [44],
despite convincing evidence of only limited antibiotic
benefit for such conditions [25,40,45-53].
The first evidence of benefit from a randomized trial of
delayed prescriptions for respiratory infections came from
a trial of antibiotics for acute sore throat carried out by Lit-
tle et al. [46], who gave either a prescription for antibiotics
to be filled immediately, or one to be filled after three
days, or no prescription for antibiotics. The "immediate
group" consumed 99% of the antibiotic prescriptions,
while the "delayed group" used only 31% with no appar-
ent negative medical consequences [46]. In an other
report, Little et al. [54] found evidence that both current
and previous antibiotic prescribing for sore throat
increased reattendance, and argues that doctors should
avoid antibiotics or offer a delayed prescription for most
patients with sore throat, in order to avoid medicalising a
self-limiting illness.
Both Norwegian [55] and Danish [56] studies show great
variation in GPs' prescription patterns for RTIs, and dem-
onstrate a lack of adherence to current guidelines [21].
The potential for improvements are important, because
community-wide antibiotic resistance reduces the effec-
tiveness of currently available drugs to combat bacterial
pathogens, and increases the individual patient's risk of
becoming infected with drug-resistant organisms [57-59].Page 3 of 12
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tional intervention strategies towards GPs. Coenen et al.
[60] reported that an (inter)actively delivered tailored
intervention implementing a guideline for acute cough in
a GP setting was successful for optimizing antibiotic pre-
scribing without affecting patients' symptom resolution.
Munck et al. [61] reported that a tailored audit of Danish
GPs' antibiotic prescriptions for RTIs through the Audit
Project Odense (APO), resulted in a reduction in prescribed
antibiotics, and that the large share proportion of broad-
spectrum antibiotics was shifted to penicillin. The inter-
vention effect in this study was significant, even two years
after the intervention [61].
Welschen et al. [62] conducted a randomized controlled
trial aimed at reducing antibiotic prescription rates for
RTIs in primary care. The intervention included; a) group
education meetings with consensus procedures and com-
munication skills training, monitoring, and feedback on
prescribing behaviour for GPs; b) group education for
GPs' assistants and for pharmacists; and c) education
materials for patients. At baseline, antibiotic prescription
rates for RTIs were almost similar in the intervention and
the control groups (27% and 29% respectively). Follow-
ing the intervention, the prescribing rate in the interven-
tion group fell to 23%, whereas it increased to 37% in the
control group (mean difference of change; – 12%). The
intervention did not influence patients' satisfaction or
hospital referral rates [62].
Flottorp et al. [63] conducted a multifaceted intervention
in 142 general practices to improve the management of
urinary tract infections (in women), and sore throat. The
intervention was based on patient educational material,
computer based decision support and reminders, an
increase in the fee for telephone consultations, and inter-
active courses for general practitioners and practice assist-
ants. In this study patients in the sore throat group were
3% less likely to receive antibiotics after the intervention,
compared to the control group [63].
In the Norwegian Møre & Romsdal Prescription Study, Roks-
tad et al. [64] performed a controlled educational inter-
vention towards GPs, aimed at improving prescriptions
for acute cystitis and insomnia. Their intervention
included mailed prescription feedback along with printed
therapeutic recommendations, and resulted in statistical
significant (although clinically moderate) improvements
in prescription patterns in the intervention group (GPs in
one district), compared to the control group (GPs in
another district) [64].
Eisenberg [65] has suggested that the core principle of
effective feedback is individualized feedback with infor-
mation on behaviour compared with specific standards: It
seems as if such feedback is more effective when delivered
face-to-face [65,66].
The results of evaluations of interventions to improve
clinical practice vary and large effects are rarely seen
[67,68]. Several educational strategies have been used.
Davies et al. [69] reviewed 777 continuous medical edu-
cation (CME) studies and found evidence that educa-
tional intervention consisting of passive dissemination of
clinical practice guidelines had only little or no effects on
practice. This corresponds with later reports by Oxman et
al. [70] and Freemantle et al. [71]. Other, more active
strategies, like educational outreach visits [72] and multi-
faceted interventions [67], are more effective, but will gen-
erally require more resources [67]. Soumerai et al. [73]
reviewed educational methods for improving prescribing
in primary care, and examined the approaches of feedback
to prescribers, mailed-out educational material, group
education and educational outreach (academic detailing),
with educational outreach having the largest impact [66].
In an extensive review, Jamtvedt et al. [74] concluded that
audit and feedback may be effective for improving profes-
sional medical practice, although the effects are generally
small to moderate. Absolute effects of audit and feedback
are more likely to be large when baseline adherence to rec-
ommended practice is low [74].
Underlying reasons for deviations between clinical prac-
tice and clinical guidelines vary from one problem to
another and from one physician to another [70]. There-
fore, it is recommended to address potential barriers to
change when tailoring an intervention targeting change in
medical performance. Because non-equivalent compari-
son groups may distort the results of evaluations, cluster-
randomized trials (in which healthcare professionals or
groups of professionals, rather than patients are rand-
omized) are more likely to provide valid results than other
research designs, such as controlled before-after or time-
series studies [75].
Objectives
The primary objective of this trial is to evaluate the effects
of a tailored intervention towards Norwegian GPs for a
more rational approach to antibiotic prescriptions for
RTIs. Our hypothesis is that an educational intervention
program carried out during a 6-month period will be
effective in improving prescribing patterns by reducing
the total number of antibiotic prescriptions, as well as
reducing the relative amount of broad-spectrum antibiot-
ics, with special emphasis on macrolides. Degree of
improvement will be measured by prevalence of specific
antibiotic prescriptions and the combination of particular
antibiotic prescriptions and selected diagnostic codes,
according to the International Classification of Primary
Care (ICPC-2) [76]. Secondary objectives are to estimatePage 4 of 12
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drugs, the latter based on dispensed drugs recorded in the
Norwegian Prescription Database (NorPD), a national
registry including data for all prescription drugs issued at
Norwegian pharmacies, established in 2004 [77]. We will
also explore effect of "delayed prescriptions" on the anti-
biotic prescription patterns.
Methods/Design
Our main hypothesis will be tested using a cluster-rand-
omized controlled trial comparing outcomes between the
intervention and control groups at follow-up. The clusters
are existing peer CME groups, comprised by GP special-
ists. These groups of GPs will be randomized to receive a
tailored intervention to support a more rational antibiotic
prescribing for RTIs, or to a control group.
Prescription data will be collected for all eligible patients
from intervention and control groups at baseline and one
year after the initiation of the trial.
Participants
In Norway, specialists in general practice must renew their
clinical specialty every five years. In this renewal process,
participation in a number of peer CME group meetings are
compulsory, in order to stimulate a continuously medical
education and reflection.
GP's in the same practice usually attend the same peer
group, according to information from the Norwegian
Medical Association. All peer groups (approximately 250)
on average consisting of seven to eight colleagues located
in the southern part of Norway, will be invited to partici-
pate in this trial. Our aim is to recruit approximately 80
peer groups or more to the current trial. Participating prac-
titioners using one of four major electronic patient record
(EPR) systems (Infodoc®, WinMed®, ProfDoc Vision® or
System X®) are eligible for the trial. More than nine out of
ten of Norwegian general practices use one of these four
EPRs, which are used routinely during consultations with
patients [78].
Intervention
We have developed an intervention through a process of
identifying inappropriate prescriptions of antibiotics for
RTIs; either as particular drugs, or drugs linked to specific
diagnosis. Identification of irrational antibiotic treatment
is based on guidelines on antibiotic prescriptions issued
by The Norwegian Board of Health 2000 [35]. This guide-
line was distributed to all Norwegian GPs in 2000 and is
also available on the Internet. Examples of suboptimal
antibiotic prescribing according to this guideline are listed
in Table 1.
In order to implement a more rational prescribing, 13 GPs
will be recruited as tutors, each with responsibility for the
intervention in three peer CME groups. Each tutor, named
Prescription Peer Academic Detailer (Rx-PAD), will
receive a four days' pre-study training program, focusing
on the evidence of antibiotic treatment of RTI, pedagogi-
cal intervention techniques, and how to install and use
the data-software program for data collection. When
recruiting Rx-PADs, emphasis is also laid on the economic
independence from any pharmaceutical manufacturers.
The tailored intervention towards the GPs in the peer
groups will include two educational outreach visits, both
performed by the same Rx-PAD. The elements of the inter-
vention are discussions within the peer group, collection
of individual prescription data, audit based on individual
feedback reports, as well as a one day regional work-shop,
see Figure 1.
In the first outreach visit, the main elements of the inter-
vention will be presented, with special emphasis on evi-
dence-based prescription of antibiotics for RTIs in out-
patients, choice of first-line drugs, and treatment goals.
During the visit, a software package will be delivered to
each participant, for installation on own practice compu-
ter with EPR. This enables the participants to extract indi-
vidual data from the preceding 12-month period. These
data will be used for feedback reports and comprise the
baseline data used in this study. For two of the four EPR
systems (WinMed® and ProfDoc Vision®), the software
package will also include computerized "pop-ups" on the
computer screen when antibiotics are prescribed, in order
to mark prescriptions as either "regular" (to be dispensed
immediately) or "delayed" (to be dispensed in n days)
(Figure 2). Data from these "pop-ups" will be integrated
in the second data extraction, and will represent a separate
factor in the subsequent data analyses. These two EPR sys-
tems are probably used by more than half of all GPs
involved in this study. Prescription data will be collected
on diskettes and analyzed by research staff, followed by an
Table 1: Examples of inappropriate antibiotic prescription patterns according to guidelines by The Norwegian Board of Health 2000
Uncomplicated acute otitis media (AOM) in children > 1 year of age with symptoms < 3 days
Acute sinusitis with moderate symptoms < 7 days
Acute tonsillitis without positive indication of infection caused by group A Streptococcus
Acute bronchitis (except verified infections caused by Mycoplasma pneumonia or Chlamydia pneumonia)
Use of broad spectrum antibiotics where penicillin V could be prescribedPage 5 of 12
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Flow of practices through The Rx-PAD Studyigure 1
Flow of practices through The Rx-PAD Study. *Electronic Patient Record, **Norwegian Prescription Database, ***Pre-
scription Peer Academic Detailer
Peer groups in the southern part of 
Norway (n~250) will be invited to 
participate  
Peer groups that 
do not consent to 
participate 
Randomization  
Approximately 1/3 of the peer groups 
recruited to the trail 
Half of recruited peer groups:  
Intervention: Antibiotics for upper 
respiratory tract infections  
Control: Prescription patterns in elderly 
 70 years 
Anticipated loss, due to drop outs and 
withdrawals, estimated to 10%
Anticipated loss, due to drop outs and 
withdrawals, estimated to 10%
Half of recruited peer groups:  
Intervention: Prescription patterns in 
elderly  70 years 
Control: Antibiotics for upper 
respiratory tract infections 
Remaining peer groups in the 
tailored intervention  
Remaining peer groups in the 
tailored intervention  
Retrospective 12 months data collection from 
EPR* and NorPD** 
Retrospective 12 months data collection from 
EPR* and NorPD** 
Intervention in peer groups including 2 visits 
by Rx-PADs***, discussions within the peer 
groups, work-shop, audit and feedback reports 
Intervention in peer groups including 2 visits by 
Rx-PADs***, discussions within the peer groups, 
work-shop, audit and feedback reports 
Retrospective 12 months data collection from 
EPR* and NorPD** 
Retrospective 12 months data collection from 
EPR* and NorPD** 
Analysis of data and preparation of 
manuscripts. Feedback to participating peer-
groups 
Analysis of data and preparation of   
manuscripts. Feedback to participating peer-
groups 
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each participant.
The second outreach visit, which will take place within
two months after the first visit, focus on the newly
revealed prescription patterns. Rx-PADs will facilitate the
discussion within the peer groups, based on individual
feedback reports, enabling participants to compare own
prescription patterns with overall averages. This will trig-
ger discussion within the peer group, aimed at critical
reflection towards own prescription strategies for RTIs and
the disclosure of areas where individual improvements
are desirable and possible.
About three months after the second outreach visit, all
participants will be gathered in regional work-shops
where evidence-based rationale behind pharmacological
treatment of RTIs in out-patients will be outlined in more
depth on the basis of baseline prescription data. Twelve
months after the first data extraction, a second data extrac-
tion of the GPs' prescribings for the preceding 12-months
period will be undertaken and new individual reports will
be sent to the participants.
Data handling
Software aimed at extracting predefined data sets will be
developed for this trial. The software will be compatible
with the four EPRs (Infodoc®, WinMed®, ProfDoc Vision®
or System X®) used by the large majority of Norwegian
GPs. The dataset from each individual GP will provide
information on number of patient appointments, and
main diagnosis linked to each appointment with patients
with a respiratory tract infection. Diagnosis will be based
on the International Classification of Primary Care (ICPC-
2) [76]. Extracted data will also contain drug prescription
details, described in terms of The Anatomical, Therapeu-
tic, Chemical (ATC) classification system with Defined
Daily Doses (DDDs), in short: The ATC/DDD system
[79].
In order to merge prescription data provided by NorPD
with data from the EPR systems, the Civil Personal Regis-
tration (CPR) number for each patient will be extracted
from the EPR. These are the unique identification num-
bers for Norwegian citizens, and will be deleted from the
research database after the record linkage has been per-
formed. The dataset from NorPD will provide data on
drugs actually dispensed.
Extracted data from each EPR will be encrypted, stored on
a diskette and mailed to the principal researcher. A flow-
chart of the data collection is summarized in Figure 3.
Outcome measures
Primary outcome measures will be changes in prescrip-
tion patterns after the tailored educational intervention in
terms of prescriptions for antibiotics in out-patients with
RTIs. The intervention will include the option of "delayed
prescriptions". Following the intervention, prescription
data will be collected one year after the first (baseline)
gathering of prescription data. Change in prescription pat-
terns in the intervention group will be compared with the
non-intervention control group, and with a sample of
Norwegian GPs not included in the current trial. The latter
data will be provided by the NorPD. Outcome measures
are summarized in Table 2.
Pilot study
The prescription data extraction procedures and the two
peer group visits will be piloted in one peer CME group,
before the main trial.
Recruitment and randomization
Block-randomization of peer CME groups will be done
within geographical strata, each comprised of one or more
counties. The size of the blocks will vary according to the
number of recruited groups within each stratum. An inde-
pendent researcher not involved in the study will be
responsible for the randomization. Based on this rand-
omization, peer groups will be assigned to either the inter-
vention group or to the control group.
Ethics and data security
Physicians participating in the peer CME groups will be
given information about the objectives of the study and
Example of pop-up on physician's computer screenFigure 2
Example of pop-up on physician's computer screen. 
The pop-up appears when the physician is about to prescribe 
antibiotics for a respiratory tract infection (RTI), and enables 
the physician to decide whether the prescription is 1) to be 
dispensed immediately or 2) to be dispensed in a specified 
number of days, with advice to the patient to wait and see if 
the condition improves spontaneously, so-called "delayed 
prescription". Type of prescription and recommended delay 
(n days) for delayed prescriptions will be registered in the 
study software installed in the physicians computer and ana-
lysed by research staff.Page 7 of 12
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will be told that each peer CME group will be randomized
to one out of two interventions (improved antibiotic pre-
scriptions for RTIs or improved prescription patterns in
elderly ≥ 70 years), and that they will serve as control
group for the intervention they do not take part in. Partic-
ipation is based on written informed consent from all
physicians. The project has been presented for The
Regional Committee for Research Ethics and approval
from The Norwegian Social Science Data Services (NSD)
has been obtained, implicating acceptance to extract pre-
scription data. In order to use patient identification data
in the merging process between NorPD and EPR data-
bases, The Directorate for Health and Social Affairs has
approved dispensation from the health-professional
secrecy.
Sample size and statistics
A prevalence of 27% of inappropriate prescriptions of
antibiotics for RTIs in general practice settings were found
in two previous studies; one from Norway [80] and one
from The Netherlands [62]. In accordance with these find-
ings [62,80], we anticipate a baseline prevalence of inap-
propriate prescription of antibiotics for RTIs of 27% in the
present study.
Flottorp et al. [63] demonstrated a 3% reduction of inap-
propriate antibiotic prescription for sore throat in a tai-
lored intervention in general practice settings. This
intervention was not, however, based on peer CME
groups. This was considerably less than the 12% reduction
(absolute value) of antibiotic prescription rates for RTIs
Logistics of data collectionFi ure 3
Logistics of data collection. Flow-chart of merging process of prescription data provided by the Norwegian Prescription 
Database (NorPD) and data from the electronic patient record (EPR) systems. Patients' Civil Personal Registration (CPR) num-
bers are unique Norwegian residents' identification keys. Health Personnel Registration (HPR) numbers are unique Norwegian 
health personnel registration keys. Identifiable data will be deleted from the research database when the merge is completed, 
as the de-identified personal IDs will be sufficient for the subsequent data analysis. Statistics Norway, which is the public insti-
tution in Norway responsible for collecting, analyzing and disseminating official statistics, will provide CPR and HPR pseudo-
nyms making it possible to merge the two data sources.
Data flowchart
Participant’s
EPR system Statistics Norway
Norwegian Prescription
Database - NorPD
(Pseudonymous) 
Project site
University of Oslo
Project IDs linked to patients’ CPR 
number and doctors’ HPR 
numbers
Project ID’s linked to 
pseudonymous CPR and 
HPR numbers 
Patients’ data linked to 
project IDs (de-identified 
personal IDs) 
Prescription data linked to 
project IDsPage 8 of 12
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tion trial.
In the present study we will consider a reduction of inap-
propriate prescriptions for RTIs by one third to be clini-
cally significant. Assuming that the prevalence of
inappropriate prescriptions in the control group remains
constant, this equals a reduction from a baseline level of
27% to a post-intervention level of 18% or less (9% abso-
lute reduction; 33% relative reduction).
The sample size calculation needs to take into account
and adjust for intra-cluster (peer group) correlation, since
the data within peer groups cannot be considered inde-
pendent. The intra-cluster correlation is assumed to be
0.085, based on data from previous studies [63,78]. Fur-
thermore, we expect an average of 7 participating doctors
per peer group (allowing for some withdrawal) and an
average of 300 cases of RTIs per GP during the interven-
tion period, amounting to a total of 2100 cases per cluster.
The variance inflation factor [81], used to correct the sam-
ple size, was therefore 179.
Based on these figures and applying an 80% power level
and a 5% statistical significance level, we estimate an
intervention sample size requirement of 31 peer CME
groups and a corresponding number of control groups.
We will carry out post-test comparisons between the inter-
vention and control group using cluster-adjusted chi-
square and t-tests. Analysis of covariance may be used to
adjust for imbalance of baseline levels between the inter-
vention- and control-groups [82]. The data set will prima-
rily be analysed according to the cluster-randomization,
however, analyses at physician- and sub-groups of physi-
cians will also be performed, based on individual patients'
data.
Discussion
A thorough evaluation of the diagnostic indications for
antibiotic treatment of RTIs may impose important bene-
fits, whereas inappropriate prescribing may lead to unde-
sirable consequences like the development of antibiotic
resistance. We have therefore developed an intervention
aimed at supporting the implementation of more rational
antibiotic prescribing patterns for RTIs in GP settings and
planned a trial to assess the effectiveness of this interven-
tion.
The control group in this study will not receive any inter-
vention towards prescriptions of antibiotics, but will be
assigned to another drug prescription trial, where they
will recieve an educational intervention for improving
their prescribing (other than antibiotics) for elderly out-
patients ≥ 70 years [83]. As such, the control group may be
susceptible to changes in their general prescription pat-
terns, i.e. a possible Hawthorne effect. To control for this,
we will be able to analyze prescription patterns for all Nor-
wegian GPs not included in the current trial, using data
from the NorPD [77]. These data, however, will not be
linked to diagnoses, and the comparison will therefore be
performed on total prescription of the different antibiot-
Table 2: Outcome measures in study of the effect of a pedagogic intervention towards groups of Norwegian GPs, concerning antibiotic 
prescription for respiratory tract infections (RTIs)
Baseline data collected during one year:
Proportion of consultations with antibiotic prescription of all consultations with respiratory tract diagnoses
Proportion of consultations with antibiotic prescription of consultations with specified RTIs
Proportion of consultations with narrow-spectrum antibiotic prescription of all antibiotic prescription
Predictors for high and low antibiotic prescription
Change as measured one year after pedagogic intervention:
Change in total antibiotic prescription for respiratory tract diagnoses
Change in proportion of consultations with antibiotic prescription of all consultations with respiratory tract diagnoses
Change in proportion of consultations with antibiotic prescription of consultations specified RTIs
Change in proportion of consultations with narrow-spectrum antibiotic prescription of all antibiotic prescription
Predictors for change in total antibiotic prescription and proportion narrow-spectrum antibiotics
Use of delayed prescriptions:
Proportion of use of delayed prescriptions by all antibiotic prescriptions for respiratory tract diagnoses
Proportion of use of delayed prescriptions by antibiotic prescriptions for specified respiratory tract diagnoses
Predictors for high/low use of delayed prescriptions
Comparisons between antibiotic prescriptions and data from the Norwegian Prescription Database (NorPD)
Proportion and delay of dispensed antibiotic prescriptions compared to prescribed antibiotics
Refund of antibiotics:
Proportion of antibiotics prescribed with full refundPage 9 of 12
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tions.
To assure a highest possible response rate from the partic-
ipating GPs, we will provide technical telephone support
during the data collection period. Furthermore, the partic-
ipants must provide data to receive an individual feedback
report. Also, the Rx-PAD will remind their group partici-
pants to send in data sets before the second peer group
meeting.
Because the aim of this study is to improve quality accord-
ing to good clinical practice, the study is not likely to
imply risks or impaired quality of care for the patients
involved. The risk of data-misuse is limited due the fact
that the research database will only be linked to de-iden-
tified patient ID numbers.
The estimated ICC-value, which will be used in the statis-
tical analyses, reflects the three different levels of cluster-
ing; each participating doctor, each clinic, and each peer
CME group. Our ability to establish an exact ICC-value is
limited, due to few comparable studies.
A reduction of inappropriate prescriptions by one third
compared to the baseline figures may seem too optimistic.
However, in the light of a previous study [62], we still
believe that this is a realistic goal.
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